Pds biotechnology reports inducement grants under nasdaq listing rule 5635(c)(4)

Florham park, n.j., oct. 21, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, today announced that on october 19, 2021 pds biotech granted nonstatutory stock options to (a) matthew hill, pds biotech's chief financial officer to purchase 202,800 shares of pds biotech common stock, (b) siva k. gandhapudi, pds biotech's director, immunology drug development, to purchase 10,000 shares of pds biotech's common stock, (c) sally jones, pds biotech's associate director, clinical operation, to purchase 12,900 shares of pds biotech's common stock, and (d) mary banoub, pds biotech's scientist, r&d, to purchase 2,500 shares of pds biotech's common stock, each in accordance with nasdaq listing rule 5635(c)(4) and pds biotech's 2019 inducement plan, as amended, which was adopted on june 17, 2019 and provides for the granting of equity awards to new employees of pds biotech.
PDSB Ratings Summary
PDSB Quant Ranking